Acute myeloblastic leukemia: Daunorubicin is indicated for the treatment of all stages of this disease, either as a single agent or in combination with other antiblastic drugs. It is also the treatment of choice for promyelocytic leukemia.
Acute lymphoblastic leukemia: Daunorubicin is very active in inducing remission in this disease. However, due to its side effects and the availability of other forms of therapy, Daunorubicin is only indicated in those cases that are resistant to other drugs. The combination chemotherapy regimen of Daunorubicin, prednisolone and vincristine in the acute phase of the disease has proved successful.
Other tumours: Positive responses have been observed with Daunorubicin in neuroblastoma and rhabdomyosarcoma.